

World Journal of *Clinical Cases*

World J Clin Cases 2020 February 6; 8(3): 487-651





REVIEW

- 487 Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries
Rare Tumors GI Group, Farhat F, Farsi AA, Mohieldin A, Bahrani BA, Sbaity E, Jaffar H, Kattan J, Rasul K, Saad K, Assi T, Morsi WE, Abood RA

CLINICAL AND TRANSLATIONAL RESEARCH

- 504 Novel zinc alloys for biodegradable surgical staples
Amano H, Miyake K, Hinoki A, Yokota K, Kinoshita F, Nakazawa A, Tanaka Y, Seto Y, Uchida H

CASE REPORT

- 517 Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report
Palleschi M, Maltoni R, Barzotti E, Melegari E, Curcio A, Cecconetto L, Sarti S, Manunta S, Rocca A
- 522 Radiation recall dermatitis with dabrafenib and trametinib: A case report
Yilmaz M, Celik U, Hascicek S
- 527 Isolated vaginal metastasis from stage I colon cancer: A case report
Kwon SK, Yu CS, Lee SW, Kim J, Song I, Lee JL, Kim CW, Yoon YS, Park JJ, Lim SB, Kim JC
- 535 Ruptured splenic peliosis in a patient with no comorbidity: A case report
Rhu J, Cho J
- 540 Successful kidney transplantation from an expanded criteria donor with long-term extracorporeal membrane oxygenation treatment: A case report
Seo HW, Lee S, Lee HY, Park SC, Chung BH, Yang CW, Ban TH
- 546 Boarding issue in a commercial flight for patients with cavitary pulmonary tuberculosis: A case report
Jo W, Pak C, Jegal Y, Seo KW
- 552 Cytomegalovirus ileo-pancolitis presenting as toxic megacolon in an immunocompetent patient: A case report
Cho JH, Choi JH
- 560 Successful treatment of adult-onset still disease caused by pulmonary infection-associated hemophagocytic lymphohistiocytosis: A case report
Wang G, Jin XR, Jiang DX

- 568** Complex liver retransplantation to treat graft loss due to long-term biliary tract complication after liver transplantation: A case report
Li J, Guo QJ, Jiang WT, Zheng H, Shen ZY
- 577** Peutz-Jeghers syndrome with mesenteric fibromatosis: A case report and review of literature
Cai HJ, Wang H, Cao N, Wang W, Sun XX, Huang B
- 587** Cutaneous nodules and a novel *GNAS* mutation in a Chinese boy with pseudohypoparathyroidism type Ia: A case report and review of literature
Li YL, Han T, Hong F
- 594** Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with *HER2* gene amplification: A case report
Jiang Q, Xie MX, Zhang XC
- 600** Large cutaneous epithelioid angiomatous nodules in a patient with nephrotic syndrome: A case report
Cheng DJ, Zheng XY, Tang SF
- 606** Clinicopathologic characteristics of prostatic stromal sarcoma with rhabdoid features: A case report
Li RG, Huang J
- 614** Erdheim-Chester disease with asymmetric talus involvement: A case report
Xia Q, Tao C, Zhu KW, Zhong WY, Li PL, Jiang Y, Mao MZ
- 624** Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report
Yu Q, Wang WX
- 630** Combined surgical and interventional treatment of tandem carotid artery and middle cerebral artery embolus: A case report
Zhang M, Hao JH, Lin K, Cui QK, Zhang LY
- 638** Sternal Hodgkin's lymphoma: A case report and review of literature
Yin YY, Zhao N, Yang B, Xin H
- 645** Esophageal tuberculosis complicated with intestinal tuberculosis: A case report
Mao L, Zhou XT, Li JP, Li J, Wang F, Ma HM, Su XL, Wang X

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Valerio D'Orazi, MD, PhD, Professor, Department of Surgical Sciences, Sapienza University of Rome, Rome 00161, Italy

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now indexed in PubMed, PubMed Central, Science Citation Index Expanded (also known as SciSearch®), and Journal Citation Reports/Science Edition. The 2019 Edition of Journal Citation Reports cites the 2018 impact factor for WJCC as 1.153 (5-year impact factor: N/A), ranking WJCC as 99 among 160 journals in Medicine, General and Internal (quartile in category Q3).

RESPONSIBLE EDITORS FOR THIS ISSUE

Responsible Electronic Editor: *Yan-Xia Xing*

Proofing Production Department Director: *Xiang Li*

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Semimonthly

EDITORS-IN-CHIEF

Dennis A Bloomfield, Bao-Gan Peng, Sandro Vento

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/2307-8960/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director

PUBLICATION DATE

February 6, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Cutaneous nodules and a novel *GNAS* mutation in a Chinese boy with pseudohypoparathyroidism type Ia: A case report and review of literature

Yun-Ling Li, Ting Han, Fang Hong

ORCID number: Yun-Ling Li (0000-0003-2389-2091); Ting Han (0000-0002-4888-1447); Fang Hong (0000-0002-5718-5005).

Author contributions: Li YL treated the patient's dermatological problems, reviewed the literature, and contributed to manuscript drafting; Han T reviewed the literature and contributed to manuscript drafting; Fang H treated the patient's endocrinological problems and contributed to manuscript drafting; all authors approved the version of the manuscript to be submitted.

Supported by the Department of Education of Zhejiang Province, No. Y201738451; Health and Family Planning Commission of Zhejiang Province, No. 2016148438.

Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in

Yun-Ling Li, Department of Dermatology, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, Zhejiang Province, China

Ting Han, Department of Children's Health Care, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, Zhejiang Province, China

Fang Hong, Department of Genetics and Metabolism, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, Zhejiang Province, China

Corresponding author: Fang Hong, PhD, Chief Physician, Director, Department of Genetics and Metabolism, The Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 3333 Bingsheng Road, Hangzhou 310052, Zhejiang Province, China. 6193008@zju.edu.cn

Abstract

BACKGROUND

Pseudohypoparathyroidism type Ia (PHP Ia) is a rare hereditary syndrome, and patients with early PHP Ia are generally not diagnosed based on the presentation of cutaneous nodules as the main clinical feature. Here, we describe a Chinese boy with PHP Ia in whom the main clinical feature was cutaneous nodules, and the patient exhibited a novel *GNAS* mutation.

CASE SUMMARY

A 5-year-old boy presented with a 5-year history of cutaneous nodules scattered over his entire body. The patient had a short stature, round face, short neck, and slightly flattened nose; he also had multiple hard papules and cutaneous nodules scattered over his entire body. The patient had a significantly elevated parathyroid hormone level. His serum calcium level was reduced, while his serum phosphorus level was increased and his serum thyroid-stimulating hormone level was elevated. Skin biopsy showed osteoma cutis in subcutaneous tissue. Sanger sequencing revealed a frameshift mutation, c.399delT (p.Ser133Argfs*2) in exon 5 of the *GNAS* gene. The patient was diagnosed with PHP Ia and subclinical hypothyroidism. He was given 1,25-dihydroxyvitamin D, calcium carbonate, and synthetic L-thyroxine. After 3 months of treatment, the patient's parathyroid hormone level decreased, and his serum calcium and serum phosphorus levels were normal. Moreover, his thyroid-stimulating hormone

accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Received: November 30, 2019

Peer-review started: November 30, 2019

First decision: December 11, 2019

Revised: January 3, 2020

Accepted: January 8, 2020

Article in press: January 8, 2020

Published online: February 6, 2020

P-Reviewer: Faia S

S-Editor: Dou Y

L-Editor: Wang TQ

E-Editor: Liu MY



level decreased.

CONCLUSION

These findings can help dermatologists to diagnose PHP Ia in patients with cutaneous nodules as the main early clinical feature.

Key words: Pseudohypoparathyroidism type Ia; Cutaneous nodules; *GNAS*; Pseudohypoparathyroidism; Case report

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Herein, we describe a Chinese boy with pseudohypoparathyroidism type Ia who presented with multiple cutaneous nodules at an early stage and exhibited a c.399delT mutation in the *GNAS* gene. This mutation was not found in public databases, including Exome Aggregation Consortium, the Genome Aggregation Database, ClinVar, and the Human Gene Mutation Database. Therefore, we concluded that the c.399delT mutation in exon 5 of the *GNAS* gene was a novel mutation associated with pseudohypoparathyroidism type Ia.

Citation: Li YL, Han T, Hong F. Cutaneous nodules and a novel *GNAS* mutation in a Chinese boy with pseudohypoparathyroidism type Ia: A case report and review of literature. *World J Clin Cases* 2020; 8(3): 587-593

URL: <https://www.wjgnet.com/2307-8960/full/v8/i3/587.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v8.i3.587>

INTRODUCTION

Pseudohypoparathyroidism (PHP) is a rare, sporadic or familial disorder characterized by an elevated plasma level of parathyroid hormone (PTH) caused by resistance to PTH action in target tissues^[1,2]. PHP was first reported in 1942 by Albright *et al*^[3] and classified into PHP type I (PHP I) and PHP type II (PHP II) according to the renal response to exogenous PTH administration. PHP I is divided into subtypes Ia, Ib, and Ic. Patients with PHP Ia display hypocalcemia, hyperphosphatemia, PTH resistance, and variable developmental abnormalities [e.g., Albright's hereditary osteodystrophy (AHO)]. PHP Ia is caused by inactivating mutations of the guanine nucleotide-binding protein, alpha-stimulating activity polypeptide (*GNAS*) gene, which encodes the alpha subunit of the stimulatory heterotrimeric G protein (G_s)^[4].

Patients with PHP Ia generally seek medical attention due to epileptic seizures, and both the misdiagnosis and missed diagnosis rates are extremely high. Here, we describe a patient with PHP Ia who presented with multiple cutaneous nodules as the main clinical feature; this patient did not experience epileptic seizures and exhibited a novel *GNAS* mutation.

CASE PRESENTATION

Chief complaints

A 5-year-old boy with a 5-year history of cutaneous nodules was referred to the Children's Hospital at Zhejiang University School of Medicine, Hangzhou, China.

History of present illness

Cutaneous nodules had been observed since the patient was 2 mo old. A hard papule and nodules were first found at the waist. Numerous similar lesions subsequently appeared on the head, trunk, and limbs; these gradually became progressively larger.

History of past illness

The patient had no significant medical history, psychiatric history, or history of substance misuse.

Personal and family history

The patient was born at a gestational age of 34 wk with a birth weight of 2.6 kg and height of 46 cm. The patient's weight was between the 6th and 10th percentiles from birth to the age of 3 mo. His weight then began to increase rapidly such that obesity was evident at the age of 4 mo (Figure 1A) and continued until the age of 9 mo (> 97th percentile). The patient's height was between the 6th and 10th percentiles from birth to the time of this report. The patient could raise his head at the age of 6 mo, sit up at the age of 1 year, and walk at the age of 2 years. The patient's mother had exhibited similar cutaneous nodules in the calf and trunk regions at the age of 26 years; she also had a short stature, round face, and was obese (Figure 1D). The patient's older brother, father, aunt, and uncle did not display similar manifestations of the disease.

Physical examination

On physical examination, the child had a short stature, round face, short neck, and slightly flattened nose (Figure 1B and C). His height was 105 cm and his weight was 19.5 kg (10th and 75th percentiles, respectively). The patient was only able to express simple sentences; his score on the Wechsler Intelligence Scale for Children was 51, which suggested mental retardation. The patient had multiple hard papules and cutaneous nodules scattered over his entire body; these cutaneous nodules measured 1 mm to 2 cm in size (Figure 2A). He exhibited no erythema, blisters, tenderness, or swelling on the surfaces of cutaneous nodules.

Laboratory examinations

Laboratory investigations showed normal findings in routine blood, urine, and stool tests, along with normal liver and renal function. The patient also had normal cortisol, adrenocorticotrophic hormone, bone type alkaline phosphatase, and 25-hydroxyvitamin D levels. His serum calcium level was 2.03 mmol/L (normal range, 2.20-2.65 mmol/L) and his serum phosphorus level was 2.91 mmol/L (normal range, 1.29-2.26 mmol/L); his serum PTH level was significantly elevated (466.2 ng/L; normal range, 15-65 ng/L). The patient had an elevated thyroid-stimulating hormone (TSH) level of 12.34 mIU/L (normal range, 0.35-4.94 mIU/L) with a normal thyroxine level of 71.87 nmol/L (normal range, 62.68-150.80 nmol/L) and a normal triiodothyronine level of 2.01 nmol/L (normal range, 0.88-2.44 nmol/L). A skin biopsy from his right thigh showed heterotopic ossification within the subcutaneous tissue, indicative of osteoma cutis (Figure 2B). Sanger sequencing showed that a c.399delT heterozygous gene mutation (NM_000516.4) was present in exon 5 of GNAS in both the patient and his mother.

Imaging examinations

Brain computed tomography examination showed multiple calcium-like high-density calcifications in the patient's scalp, but not within the brain. Electroencephalogram showed no seizure-like waves.

FINAL DIAGNOSIS

The proband was diagnosed with PHP Ia by the presence of hormone resistance, cutaneous ossification, obesity, and AHO phenotype, and maternal inheritance of the GNAS mutation. This proband had elevated TSH levels and normal T3 and T4 levels, so a diagnosis of subclinical hypothyroidism was made. Therefore, the final diagnosis of the patient was PHP Ia combined with subclinical hypothyroidism.

TREATMENT

The patient was given 1,25-dihydroxyvitamin D at a dose of 0.25 µg once daily and calcium carbonate at a dose of 300 mg once daily; he was instructed to avoid dairy, soy, and other high-phosphorus food products. Because the patient's subclinical hypothyroidism led to concerns regarding his neurologic development, he was also administered synthetic L-thyroxine at a dose of 12.5 µg once daily.

OUTCOME AND FOLLOW-UP

After 3 mo of treatment, the patient's PTH level decreased to 184.10 ng/L (normal range, 15-65 ng/L) with serum calcium and phosphorus levels of 2.24 (normal range, 2.20-2.65 mmol/L) and 2.05 mmol/L (normal range, 1.29-2.26 mmol/L), respectively; his TSH level decreased to 8.12 mIU/L (normal range, 0.35-4.94 mIU/L).



Figure 1 Photographs of the patient and his mother. A-C: The patient had severe obesity at 4 mo old (A) and a round face, short neck, flat nose at 5 years and 1 mo old (B and C); D: His mother is short and obese with a round face.

DISCUSSION

PHP is a rare autosomal dominant inherited disorder that is associated with an exon mutation in the maternal allele of the *GNAS* gene. The *GNAS* gene is located on chromosome 20q13, which consists of 13 exons and 12 introns. The product of the *GNAS* gene is Gs α , which is an important component of the cAMP/protein kinase. PTH mainly couples with Gs α through the PTH receptor to form a complex that activates adenylate cyclase and promotes the generation of cAMP, thereby regulating the cell response. *GNAS* is a complex imprinted gene encoding Gs α that exhibit exclusively maternal or paternal expression^[5]. Maternal allele of the *GNAS* gene is the only source of Gs α in the kidney (the paternal allele is normally silenced in this tissue). In PHP Ia, mutations in the maternal *GNAS* allele result in a marked reduction of Gs α levels, leading to failure to elicit an appropriate increment in urinary cAMP and phosphate excretion following exogenous PTH infusion and PTH resistance^[6]. Because the target organs (*i.e.*, the kidney and bone) do not respond to PTH, hypocalcemia feedback stimulates excessive parathyroid secretion of PTH.

The clinical manifestations of PHP Ia include signs of hypoparathyroidism, characterized by calcium and phosphorus metabolism disorders^[7-9]. Some patients also demonstrate a typical AHO phenotype, including short stature, obesity, round face, short neck, short and coarse fingers/toes, and ectopic ossification. The molecular mechanisms of *GNAS*-related heterotopic ossification have not been fully elucidated. It might involve aberrant differentiation of mesenchymal progenitor cells in the dermis or subcutaneous fat. Researchers have reported that activation of Hedgehog signaling causes *GNAS*-related heterotopic ossification. In PHP Ia with mutations in *GNAS*, Hedgehog signaling is activated in progenitor cells, which leads to heterotopic ossification and inhibition of formation of adipocytes^[10,11]. Heterotopic calcification or ossification is extremely common in patients with AHO, which mainly occurs in the subcutaneous tissue and brain parenchyma; the most common manifestation is calcification of the brain basal ganglia. Seizures can also be caused by brain parenchymal calcification and hypocalcemia. Thyroid hormone, growth hormone, and gonadotropin are mediated by Gs α ; therefore, patients with a *GNAS* mutation may present with resistance to other hormones, including TSH, growth hormone, and gonadotropin-releasing hormone. Therefore, patients with PHP Ia may exhibit hypothyroidism and hypogonadism. The patient in this case had an elevated TSH level and normal triiodothyronine and thyroxine levels; thus, a diagnosis of




Figure 2 Hard subcutaneous nodule. A: The patient had hard papules and subcutaneous nodules on the hand; B: Hematoxylin and eosin-stained biopsy taken from one hard subcutaneous nodule in the right thigh showed bone formation in subcutis ($\times 200$). Bone tissue was seen in subcutaneous tissue and bone cells (orange arrow) were surrounded by osteoblasts (black arrow).

subclinical hypothyroidism was made.

PHP Ia needs to be distinguished from PHP Ib, PTH Ic, and pseudo-PHP. PHP type Ib is a rare genomic disease that is typically sporadic; a minority of patients demonstrate autosomal dominant inheritance. PHP Ib is associated with abnormal epigenetic regulation of the *GNAS* gene due to the loss of *GNAS* promoter methylation; the *GNAS* gene coding sequence is unaltered. In addition to PTH resistance, the clinical manifestations of PHP Ib typically include resistance to many other hormones. PHP Ib is generally not accompanied by AHO characteristics, but some patients may exhibit short fingers and toes. Patients with PTH Ic exhibit AHO characteristics and resistance to multiple hormones, but have normal *Gsα* activity; thus far, the molecular and genetic mechanisms of PTH Ic remain unknown. Pseudo-PHP is a syndrome caused by a mutation of the paternal allele of the *GNAS* gene; affected patients exhibit AHO characteristics, as well as normal serum calcium and normal serum phosphorus, but lack PTH resistance.

There have been previous reports of patients with PHP Ia in whom the diagnosis was confirmed by genetic analysis. PHP Ia cases with *GNAS* mutations previously described are reviewed^[12-33] and summarized in Table 1. For example, two Korean patients with PHP Ia were confirmed to have a nonsense mutation of c.94A>T (p.Lys32X) and a known frameshift mutation of c.344_345insT (p.V117RfsX23) in the *GNAS* gene^[24]. Another study of patients with PHP Ia revealed two novel mutations: A c.569_570del mutation (p.Tyr190CysfsX19) and a splicing mutation (c.659+1G>A) in the *GNAS* gene^[25]. A Turkish boy was reported to have PHP type Ia (*GNAS* gene mutation, IVS4+5G>C); his mother had pseudo-PHP^[33]. Here, we describe a 5-year-old boy with PHP Ia who had the c.399delT (p.Ser133Argfs*2) mutation in the *GNAS* gene; his mother carried the same mutation. Notably, the C.399delT mutation of exon 5 in the *GNAS* gene is a frameshift mutation; this frameshift mutation causes AGT→AGG, resulting in an Arg to Ser amino acid variant. The second codon after this mutation site (c.399delT) becomes the stop codon (TGA), which induces early termination of translation and leads to a truncated protein associated with partial PTH resistance. We searched for this mutation in published online databases including Exome Aggregation Consortium, genome Aggregation Database, ClinVar database, and Human Gene Mutation Database; there was no information about the site in these databases. Therefore, we concluded that the c.399delT mutation in the *GNAS* gene is novel.

CONCLUSION

PHP Ia is a rare genetic disease with an extremely high rate of missed diagnosis. The findings in this report can help dermatologists to recognize and accurately diagnose PHP Ia in patients with cutaneous nodules as the main early clinical feature. If necessary, genetic testing should be conducted to confirm the diagnosis.

Table 1 GNAS gene mutations in pseudohypoparathyroidism type Ia

Mutation	Protein change	Ref.
c.753C>G	p.Ser251Arg	Warner <i>et al</i> ^[12] , 1997
c.302_303delAG	p.Glu101Glyfs*3	Yu <i>et al</i> ^[13] , 1999
c.305C>A	p.Ala102Glu	Ahrens <i>et al</i> ^[14] , 2001
c.347C>T	p.Pro116Leu	Ahrens <i>et al</i> ^[14] , 2001
c.348_349insT	p.Val117Cysfs*23	de Sanctis <i>et al</i> ^[15] , 2004
c.839G>A	p.Arg280Lys	Linglart <i>et al</i> ^[16] , 2006
c.546delC	p.Ile182Metfs*3	Gelfand <i>et al</i> ^[17] , 2007
c.191A>T	p.His64Leu	Long <i>et al</i> ^[18] , 2007
c.750C>G	p.Ser250Arg	Long <i>et al</i> ^[18] , 2007
c.637C>T	p.Gln213*	Balavoine <i>et al</i> ^[19] , 2008
c.728del	p.Thr243fs	Adegbite <i>et al</i> ^[20] , 2008
c.517G>A	p.Asp173Asn	Freson <i>et al</i> ^[21] , 2008
c.871delC	p.Leu291Serfs*44	Sun <i>et al</i> ^[22] , 2009
c.93delG	p.Lys32Argfs*26	Thiele <i>et al</i> ^[23] , 2010
c.94A>T	p.Lys32X	Park <i>et al</i> ^[24] , 2010
c.569_570del	p.Tyr190CysfsX19	Jin <i>et al</i> ^[25] , 2011
c.659+1G>A	Splicing mutation	Jin <i>et al</i> ^[25] , 2011
c.695G>A	p.Arg232His	Ishikawa <i>et al</i> ^[26] , 2011
c.85C>T	p.Gln29*	Cho <i>et al</i> ^[27] , 2013
c.457C>G	p.Leu153Val	Cho <i>et al</i> ^[27] , 2013
c.91C>T	p.Gln31*	Fernandez-Rebollo <i>et al</i> ^[28] , 2013
c.330G>C	p.Met110Ile	Fernandez-Rebollo <i>et al</i> ^[28] , 2013
c.21dupT	p.Lys8c	Elli <i>et al</i> ^[29] , 2013
c.344_345insT	p.Val117Argfs*23	Elli <i>et al</i> ^[29] , 2013
c.360delC	p.Asn121Thrfs*12	Elli <i>et al</i> ^[29] , 2013
c.860_861delTG	p.Val287Aspfs*12	Elli <i>et al</i> ^[29] , 2013
c.682C>T	p.Arg228Cys	Tam <i>et al</i> ^[30] , 2014
c.496C>T	p.Arg166Cys	Thiele <i>et al</i> ^[31] , 2015
c.568_571del	p.Asp190fs	Lemos <i>et al</i> ^[32] , 2015
IVS4+5G>C		Kirel <i>et al</i> ^[33] , 2016

*shows a termination codon mutation.

REFERENCES

- Mantovani G. Clinical review: Pseudohypoparathyroidism: diagnosis and treatment. *J Clin Endocrinol Metab* 2011; **96**: 3020-3030 [PMID: 21816789 DOI: 10.1210/jc.2011-1048]
- Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. *Endocr Rev* 2001; **22**: 675-705 [PMID: 11588148 DOI: 10.1210/edrv.22.5.0439]
- Albright F, Burnett CH, Smith PH. Pseudohypoparathyroidism: An example of 'Seabright-Bantam syndrome. *Endocrinology* 1942; **30**: 922-932
- Spiegel AM. Hormone resistance caused by mutations in G proteins and G protein-coupled receptors. *J Pediatr Endocrinol Metab* 1999; **12**(Suppl 1): 303-309
- Hayward BE, Kamiya M, Strain L, Moran V, Campbell R, Hayashizaki Y, Bonthron DT. The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. *Proc Natl Acad Sci U S A* 1998; **95**: 10038-10043 [PMID: 9707596 DOI: 10.1073/pnas.95.17.10038]
- Psychou F, Nicolaidou P, Georgouli H, Maniati-Christidis M, Dacou-Voutetakis C. Pseudohypoparathyroidism type Ia and growth hormone deficiency. Growth hormone releasing hormone receptor defect? *Hormones (Athens)* 2002; **1**: 47-50 [PMID: 17018438]
- Donghi V, Mora S, Zamproni I, Chiumello G, Weber G. Pseudohypoparathyroidism, an often delayed diagnosis: a case series. *Cases J* 2009; **2**: 6734 [PMID: 19829854 DOI: 10.1186/1757-1626-2-6734]
- Breslau NA. Pseudohypoparathyroidism: current concepts. *Am J Med Sci* 1989; **298**: 130-140 [PMID: 2669477 DOI: 10.1097/00000441-198908000-00011]
- Al-Azem H, Khan AA. Hypoparathyroidism. *Best Pract Res Clin Endocrinol Metab* 2012; **26**: 517-522 [PMID: 22863393 DOI: 10.1016/j.beem.2012.01.004]
- Lietman SA, Ding C, Cooke DW, Levine MA. Reduction in Gsalpha induces osteogenic differentiation in human mesenchymal stem cells. *Clin Orthop Relat Res* 2005; **434**: 231-238 [PMID: 15864058 DOI: 10.1097/01.blo.0000153279.90512.38]

- 11 **Bastepe M.** GNAS mutations and heterotopic ossification. *Bone* 2018; **109**: 80-85 [PMID: 28889026 DOI: 10.1016/j.bone.2017.09.002]
- 12 **Warner DR,** Gejman PV, Collins RM, Weinstein LS. A novel mutation adjacent to the switch III domain of G(S alpha) in a patient with pseudohypoparathyroidism. *Mol Endocrinol* 1997; **11**: 1718-1727 [PMID: 9328353 DOI: 10.1210/mend.11.11.0013]
- 13 **Yu D,** Yu S, Schuster V, Kruse K, Clericuzio CL, Weinstein LS. Identification of two novel deletion mutations within the Gs alpha gene (GNAS1) in Albright hereditary osteodystrophy. *J Clin Endocrinol Metab* 1999; **84**: 3254-3259 [PMID: 10487696 DOI: 10.1210/jcem.84.9.5970]
- 14 **Ahrens W,** Hiort O, Staedt P, Kirschner T, Marschke C, Kruse K. Analysis of the GNAS1 gene in Albright's hereditary osteodystrophy. *J Clin Endocrinol Metab* 2001; **86**: 4630-4634 [PMID: 11600516 DOI: 10.1210/jcem.86.10.7946]
- 15 **de Sanctis L,** Vai S, Andreo MR, Romagnolo D, Silvestro L, de Sanctis C. Brachydactyly in 14 genetically characterized pseudohypoparathyroidism type Ia patients. *J Clin Endocrinol Metab* 2004; **89**: 1650-1655 [PMID: 15070926 DOI: 10.1210/jc.2003-030850]
- 16 **Linglart A,** Mahon MJ, Kerachian MA, Berlach DM, Hendy GN, Jüppner H, Bastepe M. Coding GNAS mutations leading to hormone resistance impair in vitro agonist- and cholera toxin-induced adenosine cyclic 3',5'-monophosphate formation mediated by human XLalphas. *Endocrinology* 2006; **147**: 2253-2262 [PMID: 16484323 DOI: 10.1210/en.2005-1487]
- 17 **Gelfand IM,** Hub RS, Shore EM, Kaplan FS, Dimeglio LA. Progressive osseous heteroplasia-like heterotopic ossification in a male infant with pseudohypoparathyroidism type Ia: a case report. *Bone* 2007; **40**: 1425-1428 [PMID: 17321228 DOI: 10.1016/j.bone.2006.12.058]
- 18 **Long DN,** McGuire S, Levine MA, Weinstein LS, Germain-Lee EL. Body mass index differences in pseudohypoparathyroidism type Ia versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Galpha(s) in the development of human obesity. *J Clin Endocrinol Metab* 2007; **92**: 1073-1079 [PMID: 17164301 DOI: 10.1210/jc.2006-1497]
- 19 **Balavoine AS,** Ladsous M, Velayoudom FL, Vlaeminck V, Cardot-Bauters C, d'Herbomez M, Wemeau JL. Hypothyroidism in patients with pseudohypoparathyroidism type Ia: clinical evidence of resistance to TSH and TRH. *Eur J Endocrinol* 2008; **159**: 431-437 [PMID: 18805917 DOI: 10.1530/EJE-08-0111]
- 20 **Adegbite NS,** Xu M, Kaplan FS, Shore EM, Pignolo RJ. Diagnostic and mutational spectrum of progressive osseous heteroplasia (POH) and other forms of GNAS-based heterotopic ossification. *Am J Med Genet A* 2008; **146A**: 1788-1796 [PMID: 18553568 DOI: 10.1002/ajmg.a.32346]
- 21 **Freson K,** Izzi B, Labarque V, Van Helvoirt M, Thys C, Wittevrongel C, Bex M, Bouillon R, Godefroid N, Proesmans W, de Zegher F, Jaeken J, Van Geet C. GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets. *J Clin Endocrinol Metab* 2008; **93**: 4851-4859 [PMID: 18812479 DOI: 10.1210/jc.2008-0883]
- 22 **Sun LH,** Cui B, Zhao HY, Tao B, Wang WQ, Li XY, Ning G, Liu JM. Identification of a novel GNAS mutation for pseudohypoparathyroidism in a Chinese family. *Endocrine* 2009; **36**: 25-29 [PMID: 19381884 DOI: 10.1007/s12020-009-9193-z]
- 23 **Thiele S,** Werner R, Ahrens W, Hübner A, Hinkel KG, Höppner W, Igl B, Hiort O. Selective deficiency of Gsalpha and the possible role of alternative gene products of GNAS in Albright hereditary osteodystrophy and pseudohypoparathyroidism type Ia. *Exp Clin Endocrinol Diabetes* 2010; **118**: 127-132 [PMID: 19658058 DOI: 10.1055/s-0029-1215589]
- 24 **Park CH,** Park HD, Lee SY, Kim JW, Sohn YB, Park SW, Jin DK. Clinical, biochemical, and genetic analysis of Korean patients with pseudohypoparathyroidism type Ia. *Ann Clin Lab Sci* 2010; **40**: 261-266 [PMID: 20689139 DOI: 10.1016/j.cca.2010.02.056]
- 25 **Jin HY,** Lee BH, Choi JH, Kim GH, Kim JK, Lee JH, Yu J, Yoo JH, Ko CW, Lim HH, Chung HR, Yoo HW. Clinical characterization and identification of two novel mutations of the GNAS gene in patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism. *Clin Endocrinol (Oxf)* 2011; **75**: 207-213 [PMID: 21521295 DOI: 10.1111/j.1365-2265.2011.04026.x]
- 26 **Ishikawa Y,** Tajima T, Nakae J, Nagashima T, Satoh K, Okuhara K, Fujieda K. Two mutations of the Gsalpha gene in two Japanese patients with sporadic pseudohypoparathyroidism type Ia. *J Hum Genet* 2001; **46**: 426-430 [PMID: 11450852 DOI: 10.1007/s100380170062]
- 27 **Cho SY,** Yoon YA, Ki CS, Huh HJ, Yoo HW, Lee BH, Kim GH, Yoo JH, Kim SY, Kim SJ, Sohn YB, Park SW, Huh R, Chang MS, Lee J, Kwon Y, Maeng SH, Jin DK. Clinical characterization and molecular classification of 12 Korean patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism. *Exp Clin Endocrinol Diabetes* 2013; **121**: 539-545 [PMID: 24127307 DOI: 10.1055/s-0033-1349867]
- 28 **Fernandez-Rebollo E,** García-Cuartero B, Garin I, Largo C, Martínez F, García-Lacalle C, Castaño L, Bastepe M, Pérez de Nanclares G. Intragenic GNAS deletion involving exon A/B in pseudohypoparathyroidism type IA resulting in an apparent loss of exon A/B methylation: potential for misdiagnosis of pseudohypoparathyroidism type IB. *J Clin Endocrinol Metab* 2010; **95**: 765-771 [PMID: 20008020 DOI: 10.1210/jc.2009-1581]
- 29 **Elli FM,** deSanctis L, Ceoloni B, Barbieri AM, Bordogna P, Beck-Peccoz P, Spada A, Mantovani G. Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: the growing spectrum of GNAS inactivating mutations. *Hum Mutat* 2013; **34**: 411-416 [PMID: 23281139 DOI: 10.1002/humu.22265]
- 30 **Tam VH,** Chen SP, Mak CM, Fung LM, Lee CY, Chan AY. A novel mutation in pseudohypoparathyroidism type Ia in a Chinese woman and her son with hypocalcaemia. *Hong Kong Med J* 2014; **20**: 258-260 [PMID: 24914079 DOI: 10.12809/hkmj134025]
- 31 **Thiele S,** Werner R, Grötzinger J, Brix B, Staedt P, Struve D, Reiz B, Farida J, Hiort O. A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene. *Mol Genet Genomic Med* 2015; **3**: 111-120 [PMID: 25802881 DOI: 10.1002/mgg3.117]
- 32 **Lemos MC,** Thakker RV. GNAS mutations in Pseudohypoparathyroidism type Ia and related disorders. *Hum Mutat* 2015; **36**: 11-19 [PMID: 25219572 DOI: 10.1002/humu.22696]
- 33 **Kirel B,** Demiral M, Bozdağ Ö, Karaer K. A novel mutation in a case of pseudohypoparathyroidism type Ia. *Turk J Pediatr* 2016; **58**: 101-105 [PMID: 27922245 DOI: 10.24953/turkjp.2016.01.016]



Published By Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

